

The Protein Tyrosine Phosphatase Nonreceptor 22 (PTPN22) Is Associated With High GAD Antibody Titer in Latent Autoimmune Diabetes in Adults

Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study 3

ANTONIO PETRONE, PHD¹
 CONCETTA SURACI, MD²
 MARCO CAPIZZI, MD¹
 ANDREA GIACCARI, MD, PHD³
 EMANUELE BOSI, MD⁴
 CLAUDIO TIBERTI, ATA¹

EFISIO COSSU, MD⁵
 PAOLO POZZILLI, MD⁶
 ALBERTO FALORNI, MD⁷
 RAFFAELLA BUZZETTI, MD¹
 FOR THE NIRAD STUDY GROUP*

CONCLUSIONS— In adult-onset autoimmune diabetes, the *PTPN22* 1858T variant is associated only with a high GADA titer, providing evidence of a genetic background to clinical heterogeneity identified by GADA titer.

Diabetes Care 31:534–538, 2008

OBJECTIVE— We previously demonstrated the presence of two different populations among individuals with adult-onset autoimmune diabetes: those having either a high titer or a low titer of antibodies to GAD (GADAs). Protein tyrosine phosphatase nonreceptor type 22 (*PTPN22*) has been identified as a new susceptibility gene for type 1 diabetes and other autoimmune diseases. The aim of the present study was to evaluate whether the phenotypic heterogeneity of adult-onset autoimmune diabetes based on the GADA titer is associated with the *PTPN22* C1858T polymorphism.

RESEARCH DESIGN AND METHODS— Analysis for the C1858T polymorphism using the TaqMan assay was performed in 250 subjects with adult-onset autoimmune diabetes, divided into two subgroups with low (≤ 32 arbitrary units) or high (> 32 arbitrary units) GADA titers and 450 subjects with classic type 2 diabetes (from the Non Insulin Requiring Autoimmune Diabetes [NIRAD] Study cohort of 5,330 subjects with adult-onset diabetes) and in 558 subjects with juvenile-onset type 1 diabetes and 545 normoglycemic subjects.

RESULTS— Genotype, allele, and phenotype distributions of the *PTPN22* C1858T variant revealed similar frequencies in autoimmune diabetes with high GADA titer and juvenile-onset type 1 diabetes. An increase in TT and CT genotypes was observed in individuals with a high GADA titer compared with a low GADA titer, those with type 2 diabetes, and control subjects ($P < 0.002$ for all comparisons). The *PTPN22* 1858T allele and phenotype frequencies were increased in high GADA titer compared with a low GADA titer, type 2 diabetic, and control subjects ($P < 0.001$ for all comparisons, odds ratio 2.6).

A consistent fraction of subjects (4–10%) with adult-onset non–insulin-requiring diabetes at diagnosis, also referred to as latent autoimmune diabetes in adults or non–insulin-requiring autoimmune diabetes, has autoimmune features, specifically the presence of GAD autoantibodies (GADAs). These patients do not initially require insulin treatment and are extremely heterogeneous in terms of clinical presentation, ranging across the whole spectrum between classic phenotypes of type 1 and type 2 diabetes (1–4).

We have recently demonstrated the presence of two different populations among individuals with adult-onset autoimmune diabetes (5); analysis of GADA titers showed a bimodal distribution that identified two subgroups of patients with either a low or a high GADA titer. Compared with patients with a low GADA titer, patients with a high GADA titer had more prominent traits of insulin deficiency and a profile of more severe autoimmunity, resulting in a higher prevalence of protein tyrosine phosphatase IA-2, thyroid peroxidase antibodies, and DRB1*03-DQB1*0201 and a decreasing frequency of DQB1*0602 and DRB1*0403.

A new susceptibility gene to type 1 diabetes has been recently identified outside the HLA region, protein tyrosine phosphatase nonreceptor type 22 (*PTPN22*) (6), which encodes a lymphoid-specific phosphatase known as LYP, a powerful inhibitor of T-cell activation (7). Several studies showed that a missense single nucleotide polymorphism, C1858T, in the *PTPN22* gene is

From the ¹Department of Clinical Sciences, Sapienza University, Rome, Italy; the ²Sandro Pertini Hospital, Rome, Italy; ³Endocrinology, Catholic University, Rome, Italy; ⁴General Medicine, Diabetes and Endocrinology, San Raffaele Vita-Salute University, Milan, Italy; the ⁵Department of Endocrinology and Metabolism, University of Cagliari, Cagliari, Italy; ⁶Endocrinology, University Campus Bio-Medico, Rome, Italy; and the ⁷Department of Internal Medicine, University of Perugia, Perugia, Italy.

Address correspondence and reprint requests to Professor Raffaella Buzzetti, Department of Clinical Science, Sapienza University of Rome, Viale del Policlinico 155, 00161 Rome, Rome, Italy. E-mail: raffaella.buzzetti@uniroma1.it.

Received for publication 31 July 2007 and accepted in revised form 17 November 2007.

Published ahead of print at <http://care.diabetesjournals.org> on 4 December 2007. DOI: 10.2337/dc07-1457.

*The list of centers and physicians participating in the NIRAD Study has been published in ref. 5.

This article is dedicated to the memory of Professor Umberto Di Mario who greatly contributed to the design and implementation of the study.

Abbreviations: GADA, GAD autoantibody; NIRAD, Non Insulin Requiring Autoimmune Diabetes; *PTPN22*, protein tyrosine phosphatase nonreceptor type 22.

© 2008 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Clinical characteristics of the groups of subjects investigated

	Type 1 diabetes	High GADA titer autoimmune diabetes	Low GADA titer autoimmune diabetes	Type 2 diabetes	Control
n (male/female)	296/262	65/58	66/61	234/216	278/267
Age at diagnosis (years)	14.9 ± 7.8	49.3 ± 12.6	51.8 ± 13.3	51.6 ± 10.8	30 ± 5
BMI (kg/m ²)	18.33 ± 3.6	26.1 ± 5.03	28.2 ± 5.12	29.4 ± 5.01	21.8 ± 2.2
Fasting glucose (mg/dl)	256 ± 137	170.6 ± 62.8	165 ± 55	144 ± 48.9	78.15 ± 10
A1C (%)	10.62 ± 2.49	7.6 ± 1.7	7.1 ± 1.6	6.5 ± 1.4	—

Data are means ± SD.

associated with type 1 diabetes (6) and other autoimmune diseases (8–10); so far it is unclear how the 1858T allele can influence the activity of the LYP phosphatase. In a recent study Vang et al. (11) demonstrated that the Arg620Trp variant (which corresponds to the C1858T polymorphism: the 1858T variant changes codon 620 from arginine [Arg] to tryptophan [Trp]) is a gain-of-function form of the protein, but the mechanism by which the *PTPN22* Trp20 variant exerts the disease-promoting effect has yet to be established. Evidence has also been provided regarding a permissive role played by the *PTPN22* C1858T variant on disease progression from pre-diabetes to clinical disease (12). Finally, it has been hypothesized that the *PTPN22* polymorphism is associated primarily with autoantibody-positive autoimmune diseases (13). The aim of the present study was to study whether the phenotypic heterogeneity of adult-onset autoimmune diabetes based on the GADA titer is supported by the genetic analysis, evaluating whether the *PTPN22* C1858T polymorphism is associated with a high GADA titer instead of antibody positivity per se.

RESEARCH DESIGN AND METHODS

Four groups of patients and one of control subjects were investigated. All subjects were unrelated and of exclusively Italian origin (with parents and grandparents of Italian origin).

Adult-onset autoimmune diabetic subjects ($n = 250$) (mean ± SD age at onset 50.3 ± 12.8 years) and age- and sex-matched GADA-negative type 2 diabetic subjects ($n = 450$) (aged 51.6 ± 10.8 years) were selected from the Non Insulin Requiring Autoimmune Diabetes (NIRAD) Study cohort of 5,330 type 2 diabetic subjects recruited between February 2001 and January 2006 (4,250 from February 2001 to June 2004 [5] and an additional 1,080 from July 2004 to January 2006; the NIRAD study is an on-

going project aimed to identify autoimmune diabetic subjects for a series of clinical studies). Adult-onset autoimmune diabetic subjects were selected using the following inclusion criteria: 1) an initial diagnosis of type 2 diabetes according to the American Diabetes Association (14), 2) documented antibody positivity for GADs (15), 3) no insulin requirement and no evidence of ketosis from diagnosis to screening time, and 4) disease duration between 6 months and 5 years. Type 1 diabetic subjects ($n = 558$) (age at onset 14.9 ± 7.8 years) were recruited by participating centers of the Immunotherapy Diabetes (IMDIAB) group in the Lazio region of central Italy (16). The control group comprised normoglycemic subjects ($n = 545$) with no family history of autoimmune disorders (aged 30 ± 5 years), collected from the Blood Transfusion Service of Sapienza University of Rome. The clinical characteristics of the five groups investigated are reported in Table 1. The study was approved by all local ethics committees of participating centers, and written informed consent was obtained from all patients.

Autoantibody measurement

GADs were measured by a radiobinding assay with in vitro translated [³⁵S]methionine-labeled GAD₆₅ (15) and IA-2_{IC} (amino acids 605–979) (15). Results for GADs were converted into arbitrary units by extrapolation from a standard curve with a local standard designated 100 arbitrary units. The thresholds for positivity were determined from the 99th centile of control subjects and corresponded to 3 arbitrary units for GADs. The following performances were obtained at the first, second, and third assay proficiency evaluations of the Diabetes Antibody Standardization Program (17) performed between 2002 and 2005: sensitivity 84, 86, and 88%; and specificity 97, 97, and 92%. The intra- and inter-assay coefficients of variation of GADA for

control samples designated at 10 GADA arbitrary units were 9 and 17%, respectively. The distribution of GADA titer in patients with autoimmune diabetes was independent of diabetes duration and showed a bimodal distribution. Consistent with this observation, patients with autoimmune diabetes (GADA titer >3 arbitrary units) were divided into subgroups representing the two distributions, namely low (taken to be ≤32 arbitrary units) and high (>32 arbitrary units) GADA titer. Samples with low GADA titer were validated for GAD-specific binding by a competition assay with an excess of cold insulin (5). Based on the Diabetes Antibody Standardization Program as a reference (17), the threshold of 32 arbitrary units was equivalent to 300 World Health Organization units (5).

HLA and *PTPN22* genotyping

Genomic DNA was extracted using the salting out method (18). HLA-DRB1 and DQB1 typing was performed using allele group-specific amplifications. A reverse line blot method, kindly provided by H.A. Erlich and T. Bugawan (Roche Molecular Systems, Alameda, CA), was used as the detection system (19). The C1858T was genotyped using the fluorogenic 5' nuclease assay application of the ABI PRISM 7900 HT Sequence Detection System (Applied Biosystems, Foster City, CA). The genotyping was performed using the following primers: forward, 5'-CAA CTGCTCCAAGGATAGATGATGA-3'; reverse, 5'-CCAGCTTCCTCCTCAAC CAATAAATG-3'; and TaqMan MGB probes Fam TCAGGTGTCCTGACAGG and Vic TCAGGTGTGTCCTACAGG.

Of the 10 ng/μl stock of DNA, 4 μl was dispensed into 384-well PCR plates using a Biomek FX robot (Beckman Coulter, Fullerton, CA) to which 2 μl of a mix containing primers, MGB probes, and TaqMan Universal PCR Master Mix (Applied Biosystems) was added in accordance with the manufacturer's instruc-

Table 2—Distribution of genotype, allele, and phenotype frequencies of the PTPN22 C1858T polymorphism in type 1 diabetic, autoimmune diabetic according to GADA titer, type 2 diabetic, and control subjects

	Type 1 diabetes	High GADA titer autoimmune diabetes	Low GADA titer autoimmune diabetes	Type 2 diabetes	Control
<i>n</i>	558	123	127	450	545
Genotypes*					
C1858C	448 (80.3)	98 (79.7)	120 (94.5)	424 (94.2)	496 (91.1)
C1858T	105 (18.8)	24 (19.5)	7 (5.5)	25 (5.6)	47 (8.6)
T1858T	5 (0.9)	1 (0.8)	0 (0)	1 (0.2)	2 (0.4)
Alleles†					
C	1001 (89.6)	220 (89.5)	247 (97.3)	873 (97)	1039 (95.4)
T	115 (10.4)	26 (10.5)	7 (2.7)	27 (3)	51 (4.6)
Phenotypes‡					
CT/TT genotypes	110 (19.7)	25 (20.3)	7 (5.5)	26 (5.8)	49 (9)
CC genotype	448 (80.3)	98 (79.7)	120 (94.5)	424 (94.2)	496 (91)

Data are *n* (%). * χ^2 3 × 2 high GADA titer vs. low GADA titer, type 2 diabetic, and control subjects, $P \leq 0.008$ after Bonferroni correction. Type 1 diabetic vs. low GADA titer, type 2 diabetic, and control subjects, $P \leq 0.002$ after Bonferroni correction. † χ^2 2 × 2 high GADA titer vs. low GADA titer, type 2 diabetic, and control subjects, $P \leq 0.003$ after Bonferroni correction. Type 1 diabetic vs. low GADA titer, type 2 diabetic, and control subjects, $P < 0.0001$ after Bonferroni correction. ‡ χ^2 2 × 2 high GADA titer vs. low GADA titer and type 2 diabetic and control subjects (OR 2.6 [95% CI 1.5–4.4]), $P \leq 0.002$ after Bonferroni correction. Type 1 diabetic vs. low GADA titer, type 2 diabetic, and control subjects, $P < 0.0001$ after Bonferroni correction.

tions. These were sealed with optical seals (Applied Biosystems) and incubated at 95°C for 10 min followed by 40 cycles at 95°C for 15 s and 60°C for 1 min before analysis on a 7900HT plate reader (Applied Biosystems).

Statistical analysis

Statistical analysis was performed using SPSS (version 13; SPSS, Chicago, IL). Genotype, allele, and phenotype frequency distributions were compared using the χ^2 test or Fisher's exact test when the criteria of the χ^2 test were not fulfilled. Allele and genotype frequencies of the PTPN22 C1858T were in Hardy-Weinberg equilibrium in all groups analyzed. We considered all $P < 0.05$ values as statistically significant. A Bonferroni correction of a factor 4 was applied. Based on an odds ratio (OR) of 2.31 conferred by the 1858T variant in a previous study (6) and on preliminary evaluations, the present study should be able to identify statistical differences between type 1 diabetic, high GADA titer, low GADA titer, type 2 diabetic, and control subjects with a power of 75% and P value of 5%. Conditioning analysis based on HLA risk genotypes was also performed. HLA genotypes were classified in three risk categories (high, moderate, and low) based on the absolute risk values for type 1 diabetes previously estimated in Italian population (18). HLA genotypes were introduced as a dichotomous variable in the analysis as follows: high and moderate risk = 1, low risk = 0 (high-risk genotype: DRB1*03-DQB1*0201/DRB1*04-DQB1*0302

[DRB1*04 different from DRB1*0403]; moderate risk genotypes: DRB1*04-DQB1*0302/DRB1*04-DQB1*0302, DRB1*03-DQB1*0201/DRB1*03-DQB1*0201, DRB1*04-DQB1*0302/X, and DRB1*03/X [X different from DRB1*03, DRB1*0403-DQB1*0302, and DQB1*0602/03]; and low-risk genotypes: all the other genotypes) (18).

RESULTS— Table 2 shows the genotype, allele, and phenotype frequencies of the PTPN22 C1858T variant in type 1 diabetic, high GADA titer, low GADA titer, type 2 diabetic, and control subjects. The analysis of the PTPN22 C1858T variant revealed similar frequencies in subjects with type 1 diabetes and high GADA titers regarding genotype, allele, and phenotype distributions; the risk conferred by the 1858T variant in type 1 diabetes (OR 2.48, 95% CI 1.7–3.5) resulted independently from age at disease onset (data not shown). No significant differences in the frequencies were observed between low GADA titer, type 2 diabetic, and control subjects. Conversely, a significant increase in T1858T and C1858T genotypes was observed in high GADA titer compared with low GADA titer, type 2 diabetic, and control subjects ($P \leq 0.002$ for all comparisons).

The PTPN22 1858T allele frequency was significantly increased in high GADA titer (10.5%) compared with low GADA titer (2.7%), type 2 diabetic (3%), and control subjects (4.6%) ($P < 0.0001$ for all comparisons). The frequency of 1858T carriers was significantly increased in

high GADA titer (20.3%) compared with low GADA titer (5.5%), type 2 diabetic (5.8%), and control groups (9%) ($P < 0.001$ comparisons) conferring an OR of 2.6 (95% CI 1.5–4.4). No differences were observed in the C1858T genotype distribution between men and women (data not shown). Moreover, no significant differences were observed in the frequency of the 1858T allele between subjects carrying high and moderate HLA risk genotypes and those carrying low HLA risk genotypes either in high or low GADA titer subjects (Table 3).

CONCLUSIONS— In the present study we have shown that the PTPN22 1858T variant is associated only with high GADA titer adult-onset autoimmune diabetes, giving important support to our previous findings in which the GADA titer identified two subgroups of subjects (with high or low GADA titers) with differences in clinical phenotype supported by a different HLA class II susceptibility (5). Our results further extend previous studies indicating an association between the PTPN22 gene variant and classic type 1 diabetes in young subjects (6). The reported association of this variant with other autoimmune diseases such as rheumatoid arthritis (8), systemic lupus erythematosus (9), Graves' disease (10), and Hashimoto's thyroiditis (20) underscore the importance of the product of the PTPN22 gene in the immune regulation. Kyogoku et al. (9) proposed that the C1858T polymorphism of the PTPN22 gene may predispose individuals to auto-

Table 3—Distribution of genotype, allele, and phenotype frequencies of the PTPN22 C1858T polymorphism in subjects carrying high and moderate HLA risk genotypes and in low HLA risk genotypes with either high or low GADA titer

	High GADA titer autoimmune diabetes (n = 123)		Low GADA titer autoimmune diabetes (n = 127)	
	High and moderate HLA risk*	Low HLA risk†	High and moderate HLA risk*	Low HLA risk†
n	42	81	35	92
Genotypes				
C1858C	33 (78.6)	65 (80.2)	33 (94.3)	87 (94.6)
C1858T	8 (19)	16 (19.8)	2 (5.7)	5 (5.4)
T1858T	1 (2.4)	0 (0)	0 (0)	0 (0)
Alleles				
C	74 (88.1)	146 (90.1)	68 (97.1)	179 (97.3)
T	10 (11.9)	16 (9.9)	2 (2.9)	5 (2.7)
Phenotypes				
CT/TT genotypes	9 (21.4)	16 (19.8)	2 (5.7)	5 (5.4)
CC genotype	33 (78.6)	65 (80.2)	33 (94.3)	87 (94.6)

Data are n (%). *High-risk genotypes: DRB1*03-DQB1*0201/DRB1*04-DQB1*0302 genotype (DRB1*04 different from 0403); moderate-risk genotypes: DRB1*04-DQB1*0302/DRB1*04-DQB1*0302, DRB1*03-DQB1*0201/DRB1*03-DQB1*0201, DRB1*04-DQB1*0302/X, and DRB1*03/X (X different from DRB1*03, DRB1*0403-DQB1*0302, or DQB1*0602/03) genotypes. †Low risk genotypes: all the other genotypes.

immune disease by facilitating the generation of certain disease-associated autoantibodies, thereby contributing to disease progression. Thus, the existence of humoral abnormalities in the *PTPN22* knockout mouse, the ortholog mouse gene of *PTPN22*, is consistent with the fact that autoantibody production is a prominent feature of all human autoimmune diseases that are significantly associated with the *PTPN22* C1858T gene variant (20). Overall these data suggest that the *PTPN22* gene plays a role in autoantibody-related autoimmune diseases as recently supported by data in systemic lupus erythematosus (9).

In type 1 diabetes, early histological and functional studies indicate that the disease is caused by T lymphocytes infiltrating the β -cells (21). The disease-specific immune events are, however, reflected in the appearance of β -cell-specific autoantibodies, which are useful tools for prediction of progression to clinical disease (22,23). In this view, the present findings support and extend our previous study, demonstrating an association of *PTPN22* exclusively with high GADA titer, thus suggesting that the C1858T gene variant may be associated to autoimmune diseases only when autoantibodies are a marker of pathogenic cell destruction.

The *PTPN22* C1858T variant has been found to be a marker of disease progression and to regulate diabetes-specific autoimmunity (12). This progression was demonstrated by a fourfold higher risk of developing an additional autoantibody carried out by islet cell antibody-positive

children possessing the *PTPN22* T1858T genotype compared with children with the CC genotype. Altered LYP function, codified by the 1858T variant in CD4⁺CD25⁺ T regulatory cells to make them less potent in suppressing immune response could explain more aggressive β -cell destruction and consequently a major loss in β -cell function in patients carrying this gene variant (24).

In summary, the association of this genetic variant with high GADA titer autoimmune diabetes supports the hypothesis that in these subjects the autoimmune process induces diabetes with no major contribution from other concomitant pathogenic processes. On the other hand, the lack of association with low GADA titer autoimmune diabetes, possibly reflecting a less intense autoimmune process, implies that the appearance of a low GADA titer alone seems not to be related to the diabetes-specific autoimmune process (5). Finally, our data suggest that the *PTPN22* 1858T variant controlling T cells is involved in humoral autoimmunity.

Acknowledgments— This study was sponsored by the Foundation for the Research of Società Italiana di Diabetologia (Fo.ri.SID) based on an unconditioned research grant from Novo Nordisk, Italy.

The authors are indebted to Professors Riccardo Giorgino and Riccardo Vigneri of Fo.ri.SID for their valuable and continuous support. We also acknowledge the IMDIAB group, Rome, for providing genetic data on their type 1 diabetic patients.

References

1. Turner R, Stratton I, Horton V, Manley S, Zimmet P, Mackay IR, Shattock M, Bottazzo GF, Holman R: UKPDS 25: autoantibodies to islet-cell cytoplasm and glutamic acid decarboxylase for prediction of insulin requirement in type 2 diabetes: UK Prospective Diabetes Study Group. *Lancet* 350:1288–1293, 1997
2. Bottazzo GF, Bosi E, Cull CA, Bonifacio E, Locatelli M, Zimmet P, Mackay IR, Holman RR: IA-2 antibody prevalence and risk assessment of early insulin requirement in subjects presenting with type 2 diabetes (UKPDS 71). *Diabetologia* 48:703–708, 2005
3. Tuomi T, Carlsson A, Li H, Isomaa B, Miettinen A, Nilsson A, Nissen M, Ehrnstrom BO, Forsen B, Snickars B, Lahti K, Forsblom C, Saloranta C, Taskinen MR, Groop LC: Clinical and genetic characteristics of type 2 diabetes with and without GAD antibodies. *Diabetes* 48:150–157, 1999
4. Zinman B, Kahn SE, Haffner SM, O'Neill MC, Heise MA, Freed MI, ADOPT Study Group: Phenotypic characteristics of GAD antibody-positive recently diagnosed patients with type 2 diabetes in North America and Europe. *Diabetes* 53:3193–3200, 2004
5. Buzzetti R, Di Pietro S, Giaccari A, Petrone A, Locatelli M, Suraci C, Capizzi M, Arpi ML, Bazzigaluppi E, Dotta F, Bosi E, Non Insulin Requiring Autoimmune Diabetes Study Group: High titer of autoantibodies to GAD identifies a specific phenotype of adult-onset autoimmune diabetes. *Diabetes Care* 30:932–938, 2007
6. Bottini N, Musumeci L, Alonso A, Rahmouni S, Nika K, Rostamkhani M, MacMurray J, Meloni GF, Lucarelli P, Pellicchia M, Eisenbarth GS, Comings D,

- Mustelin T: A functional variant of lymphoid tyrosine phosphatase is associated with type 1 diabetes. *Nat Genet* 36:337–338, 2004
7. Cloutier JF, Veillette A: Cooperative inhibition of T-cell antigen receptor signaling by a complex between a kinase and a phosphatase. *J Exp Med* 189:111–121, 1999
 8. Begovich AB, Carlton VE, Honigberg LA, Schrodi SJ, Chokkalingam AP, Alexander HC, Ardlie KG, Huang Q, Smith AM, Spoerke JM, Conn MT, Chang M, Chang SY, Saiki RK, Catanese JJ, Leong DU, Garcia VE, McAllister LB, Jeffery DA, Lee AT, Batliwalla F, Remmers E, Criswell LA, Seldin MF, Kastner DL, Amos CI, Sninsky JJ, Gregersen PK: A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis. *Am J Hum Genet* 75:330–337, 2004
 9. Kyogoku C, Langefeld CD, Ortmann WA, Lee A, Selby S, Carlton VE, Chang M, Ramos P, Baechler EC, Batliwalla FM, Novitzke J, Williams AH, Gillett C, Rodine P, Graham RR, Ardlie KG, Gaffney PM, Moser KL, Petri M, Begovich AB, Gregersen PK, Behrens TW: Genetic association of the R620W polymorphism of protein tyrosine phosphatase PTPN22 with human SLE. *J Hum Genet* 75:504–507, 2004
 10. Velaga MR, Wilson V, Jennings CE, Owen CJ, Herington S, Donaldson PT, Ball SG, James RA, Quinton R, Perros P, Pearce SH: The codon 620 tryptophan allele of the lymphoid tyrosine phosphatase (LYP) gene is a major determinant of Graves' disease. *J Clin Endocrinol Metab* 89:5862–5865, 2004
 11. Vang T, Congia M, Macis MD, Musumeci L, Orru V, Zavattari P, Nika K, Tautz L, Tasken K, Cucca F, Mustelin T, Bottini N: Autoimmune-associated lymphoid tyrosine phosphatase is a gain-of-function variant. *Nat Genet* 37:1317–1319, 2005
 12. Hermann R, Lipponen K, Kiviniemi M, Kakko T, Veijola R, Simell O, Knip M, Ilonen J: Lymphoid tyrosine phosphatase (LYP/PTPN22) Arg620Trp variant regulates insulin autoimmunity and progression to type 1 diabetes. *Diabetologia* 49:1198–1208, 2006
 13. Lee YH, Rho YH, Choi SJ, Ji JD, Song GG, Nath SK, Harley JB: The PTPN22 C1858T functional polymorphism and autoimmune diseases—a meta-analysis. *Rheumatology (Oxford)* 46:49–56, 2007
 14. Palmer JP, Fleming GA, Greenbaum CJ, Herold KC, Jansa LD, Kolb H, Lachin JM, Polonsky KS, Pozzilli P, Skyler JS, Steffes MW: C-peptide is the appropriate outcome measure for type 1 diabetes clinical trials to preserve β -cell function: report of an ADA workshop, 21–22 October 2001. *Diabetes* 53:250–264, 2004
 15. Bonifacio E, Genovese S, Braghi S, Bazzigaluppi E, Lampasona V, Bingley PJ, Rogge L, Pastore MR, Bognetti E, Bottazzo GF, Gale EAM, Bosi E: Islet autoantibody markers in insulin dependent diabetes: risk assessment strategies yielding high sensitivity. *Diabetologia* 38:816–822, 1995
 16. Visalli N, Sebastiani L, Adorisio E, Conte A, De Cicco AL, D'Elia R, Manfrini S, Pozzilli P, IMDIAB Group: Environmental risk factors for type 1 diabetes in Rome and province. *Arch Dis Child* 88:695–698, 2003
 17. Bingley PJ, Bonifacio E, Mueller PW: Diabetes Antibody Standardization Program: first assay proficiency evaluation. *Diabetes* 52:1128–1136, 2003
 18. Buzzetti R, Galgani A, Petrone A, Del Buono ML, Erlich HA, Bugawan TL, Lorini R, Meschi F, Multari G, Pozzilli P, Locatelli M, Bottazzo G, Di Mario U: Genetic prediction of type 1 diabetes in a population with low frequency of HLA risk genotypes and low incidence of the disease (the DIABFIN study). *Diabetes Metab Res Rev* 20:137–143, 2004
 19. Erlich H, Bugawan T, Begovich AB, Scharf S, Griffith R, Saiki R, Higuchi R, Walsh PS: HLA-DR, DQ and DP typing using PCR amplification and immobilized probes. *Eur J Immunogenet* 18:33–55, 1991
 20. Criswell LA, Pfeiffer KA, Lum RF, Gonzales B, Novitzke J, Kern M, Moser KL, Begovich AB, Carlton VE, Li W, Lee AT, Ortmann W, Behrens TW, Gregersen PK: Analysis of families in the multiple autoimmune disease genetics consortium (MADGC) collection: the PTPN22 620W allele associates with multiple autoimmune phenotypes. *Am J Hum Genet* 76:561–571, 2005
 21. Roep BO, Arden SD, de Vries RR, Hutton JC: T-cell clones from a type-1 diabetes patient respond to insulin secretory granule proteins. *Nature* 345:632–634, 1990
 22. Ziegler AG, Hummel M, Schenker M, Bonifacio E: Autoantibody appearance and risk for development of childhood diabetes in offspring of parents with type 1 diabetes: the 2-year analysis of the German BABYDIAB Study. *Diabetes* 48:460–468, 1999
 23. Kukko M, Kimpimaki T, Korhonen S, Kupila A, Simell S, Veijola R, Simell T, Ilonen J, Simell O, Knip M: Dynamics of diabetes-associated autoantibodies in young children with human leukocyte antigen-conferred risk of type 1 diabetes recruited from the general population. *J Clin Endocrinol Metab* 90:2712–2717, 2005
 24. Bottini N, Vang T, Cucca F, Mustelin T: Role of PTPN22 in type 1 diabetes and other autoimmune diseases. *Semin Immunol* 18:207–213, 2006